Advertisement
Canada markets close in 4 hours 19 minutes

  • S&P/TSX

    21,952.44
    +10.28 (+0.05%)
     

  • S&P 500

    5,501.96
    +19.09 (+0.35%)
     

  • DOW

    39,294.26
    +130.20 (+0.33%)
     

  • CAD/USD

    0.7308
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    81.31
    -0.43 (-0.53%)
     

  • Bitcoin CAD

    83,297.27
    -1,019.99 (-1.21%)
     

  • CMC Crypto 200

    1,269.03
    -14.80 (-1.15%)
     

  • GOLD FUTURES

    2,338.50
    +1.90 (+0.08%)
     

  • RUSSELL 2000

    2,047.65
    +9.31 (+0.46%)
     

  • 10-Yr Bond

    4.3270
    +0.0390 (+0.91%)
     

  • NASDAQ

    17,918.40
    +59.71 (+0.33%)
     

  • VOLATILITY

    12.20
    -0.04 (-0.33%)
     

  • FTSE

    8,175.49
    -4.19 (-0.05%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • CAD/EUR

    0.6816
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AFTER COOL U.S. PCE DATA RAISE RATE-CUT HOPES

Fed's preferred inflation gauge shows prices rose at slowest pace since March 2021

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

Clene Inc.
·1 min read
Clene Inc.
Clene Inc.

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference and host 1x1 investor meetings.

Date: June 27, 2024
Time of Presentation: Available upon demand
Format: Fireside Chat
1x1 Meetings: Please contact your HCW representative

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here.

ADVERTISEMENT

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310

 

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856